Loading
A phase 2 trial of Paclitaxel / nab-paclitaxel in small-cell lung cancer, run by Puma Biotechnology, Inc., now recruiting.
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) is a phase 2 interventional study registered as NCT07465757 by Puma Biotechnology, Inc., with 50 participants planned, started 2026-09-30 and due to reach its primary completion in 2028-03-31. Interventions recorded: Alisertib, Alisertib, Alisertib, Alisertib, Alisertib. Conditions listed: Small Cell Lung Cancer ( SCLC ). No results are recorded here; the registry entry is the source.
Shares Alisertib, Puma Biotechnology, Small-cell lung cancer.
Shares Alisertib, Puma Biotechnology.